http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105177168-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-154 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886 |
| filingDate | 2015-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-04-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2018-04-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-105177168-B |
| titleOfInvention | Kit based on cervical liquid-based cells Yu DNA methylation examination early cervical carcinoma |
| abstract | The invention discloses a kind of kit based on cervical liquid-based cells Yu DNA methylation examination early cervical carcinoma, including orange G 6, brilliant green liquid, Bismarck Brown R liquid, Eosin Y liquid, QlAamp DNA Mini Kit kits, QIAamp EpiTect Bisulfite Kits kits, the forward primer sequence of JAM3 M4 is as shown in SEQ ID No.6, reverse primer sequences are as shown in SEQ ID No.7, the forward primer sequence of β actin is as shown in SEQ ID No.16, reverse primer sequences are as shown in SEQ ID No.17, PCR reaction solution.The present invention is used for the kit of cervical carcinoma early screening, and the further verification of the preliminary and substantial amounts of cervical exfoliated cell of detection sensitivity, specificity, positive predictive value and negative predictive value through clinical tissue sample, reaches the requirement of clinical diagnosis. |
| priorityDate | 2015-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 40.